Literature DB >> 12876031

MR imaging-guided vascular procedures using CO2 as a contrast agent.

Frank K Wacker1, Robbert M Maes, Jack A Jesberger, Sherif G Nour, Jeffrey L Duerk, Jonathan S Lewin.   

Abstract

OBJECTIVE: The purpose of this study was to test the use of CO(2) as a black blood contrast agent for MR imaging-guided vascular procedures in an animal model.
MATERIALS AND METHODS: Repeated intraarterial CO(2) injections were performed through a catheter located in the aorta and the renal arteries of three fully anesthetized pigs. Real-time images were acquired using a steady-state free precession sequence.
RESULTS: During the CO(2) injections, the bright blood in the aorta and the main renal artery was totally replaced, and this procedure resulted in an immediate, statistically significant signal loss in the vessel lumen. In more peripheral vessels, CO(2) improved the vessel conspicuity substantially. Confirmation of vessel patency distal to the catheter tip position was possible.
CONCLUSION: The use of carbon dioxide in combination with a bright blood MR imaging sequence improves vessel conspicuity and provides immediate information about blood flow distal to the catheter. This technique may be used to facilitate MR imaging-guided intravascular procedures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876031     DOI: 10.2214/ajr.181.2.1810485

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  2 in total

Review 1.  An overview on the advances in cardiovascular interventional MR imaging.

Authors:  Olaf Saborowski; Maythem Saeed
Journal:  MAGMA       Date:  2007-05-09       Impact factor: 2.310

2.  Deuterium oxide as a contrast medium for real-time MRI-guided endovascular neurointervention.

Authors:  Lin Chen; Jing Liu; Chengyan Chu; Zheng Han; Nirhbay Yadav; Jiadi Xu; Renyuan Bai; Verena Staedtke; Monica Pearl; Piotr Walczak; Peter van Zijl; Miroslaw Janowski; Guanshu Liu
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.